{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:22:10Z","timestamp":1781295730768,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,7,31]],"date-time":"2015-07-31T00:00:00Z","timestamp":1438300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12943-015-0413-2","type":"journal-article","created":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T12:42:47Z","timestamp":1438260167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-\u03baB mediated uPAR activation"],"prefix":"10.1186","volume":"14","author":[{"given":"Maria Victoria","family":"Maliandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mato-Berciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Sobrevals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebl","family":"Rou\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabel","family":"Jos\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Fillat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,31]]},"reference":[{"key":"413_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9\u201329.","journal-title":"CA Cancer J Clin"},{"key":"413_CR2","first-page":"555","volume":"9","author":"JR Hecht","year":"2003","unstructured":"Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, et al. A phase I\/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res. 2003;9:555\u201361.","journal-title":"Clin Cancer Res"},{"key":"413_CR3","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1593\/neo.81674","volume":"11","author":"M Huch","year":"2009","unstructured":"Huch M, Gros A, Jose A, Gonzalez JR, Alemany R, Fillat C. Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models. Neoplasia. 2009;11:518\u201328. 514 p following 528.","journal-title":"Neoplasia"},{"key":"413_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.scr.2013.09.008","volume":"12","author":"L Sobrevals","year":"2014","unstructured":"Sobrevals L, Mato-Berciano A, Urtasun N, Mazo A, Fillat C. uPAR-controlled oncolytic adenoviruses eliminate cancer stem cells in human pancreatic tumors. Stem Cell Res. 2014;12:1\u201310.","journal-title":"Stem Cell Res"},{"key":"413_CR5","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403\u201313.","journal-title":"J Clin Oncol"},{"key":"413_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"413_CR7","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/gt.2011.141","volume":"18","author":"G Cherubini","year":"2011","unstructured":"Cherubini G, Kallin C, Mozetic A, Hammaren-Busch K, Muller H, Lemoine NR, et al. The oncolytic adenovirus AdDeltaDelta enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models. Gene Ther. 2011;18:1157\u201365.","journal-title":"Gene Ther"},{"key":"413_CR8","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1158\/1078-0432.CCR-08-2008","volume":"15","author":"S Leitner","year":"2009","unstructured":"Leitner S, Sweeney K, Oberg D, Davies D, Miranda E, Lemoine NR, et al. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin Cancer Res. 2009;15:1730\u201340.","journal-title":"Clin Cancer Res"},{"key":"413_CR9","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1111\/j.1349-7006.2009.01289.x","volume":"100","author":"AR Nelson","year":"2009","unstructured":"Nelson AR, Davydova J, Curiel DT, Yamamoto M. Combination of conditionally replicative adenovirus and standard chemotherapies shows synergistic antitumor effect in pancreatic cancer. Cancer Sci. 2009;100:2181\u20137.","journal-title":"Cancer Sci"},{"key":"413_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.canlet.2010.01.034","volume":"294","author":"M Onimaru","year":"2010","unstructured":"Onimaru M, Ohuchida K, Nagai E, Mizumoto K, Egami T, Cui L, et al. Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer. Cancer Lett. 2010;294:178\u201386.","journal-title":"Cancer Lett"},{"key":"413_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1476-4598-10-98","volume":"10","author":"MK Kim","year":"2011","unstructured":"Kim MK, Jeon YK, Woo JK, Choi Y, Choi DH, Kim YH, et al. The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-kappaB activity and down-regulating Bfl-1. Mol Cancer. 2011;10:98.","journal-title":"Mol Cancer"},{"key":"413_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1593\/neo.81686","volume":"11","author":"S Rejiba","year":"2009","unstructured":"Rejiba S, Bigand C, Parmentier C, Hajri A. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS\/RR siRNA strategies. Neoplasia. 2009;11:637\u201350.","journal-title":"Neoplasia"},{"key":"413_CR13","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1046\/j.1432-1327.2000.01350.x","volume":"267","author":"Y Wang","year":"2000","unstructured":"Wang Y, Dang J, Wang H, Allgayer H, Murrell GA, Boyd D. Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. Eur J Biochem. 2000;267:3248\u201354.","journal-title":"Eur J Biochem"},{"key":"413_CR14","first-page":"167","volume":"2010","author":"F Li","year":"1805","unstructured":"Li F, Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta. 1805;2010:167\u201380.","journal-title":"Biochim Biophys Acta"},{"key":"413_CR15","doi-asserted-by":"publisher","first-page":"6513","DOI":"10.2174\/1381612820666140826152420","volume":"20","author":"C Fillat","year":"2014","unstructured":"Fillat C, Maliandi MV, Mato-Berciano A, Alemany R. Combining oncolytic virotherapy and cytotoxic therapies to fight cancer. Curr Pharm Des. 2014;20:6513\u201321.","journal-title":"Curr Pharm Des"},{"key":"413_CR16","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1017\/S1462399411001876","volume":"13","author":"S Wennier","year":"2011","unstructured":"Wennier S, Li S, McFadden G. Oncolytic virotherapy for pancreatic cancer. Expert Rev Mol Med. 2011;13:e18.","journal-title":"Expert Rev Mol Med"},{"key":"413_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nbt0615-569","volume":"33","author":"C Sheridan","year":"2015","unstructured":"Sheridan C. First oncolytic virus edges towards approval in surprise vote. Nat Biotechnol. 2015;33:569\u201370.","journal-title":"Nat Biotechnol"},{"key":"413_CR18","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00280-007-0567-8","volume":"61","author":"I Watanabe","year":"2008","unstructured":"Watanabe I, Kasuya H, Nomura N, Shikano T, Shirota T, Kanazumi N, et al. Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer. Cancer Chemother Pharmacol. 2008;61:875\u201382.","journal-title":"Cancer Chemother Pharmacol"},{"key":"413_CR19","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/cgt.2011.45","volume":"18","author":"M Bhattacharyya","year":"2011","unstructured":"Bhattacharyya M, Francis J, Eddouadi A, Lemoine NR, Hallden G. An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. Cancer Gene Ther. 2011;18:734\u201343.","journal-title":"Cancer Gene Ther"},{"key":"413_CR20","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1158\/1535-7163.MCT-08-0901","volume":"8","author":"D Liu","year":"2009","unstructured":"Liu D, Kojima T, Ouchi M, Kuroda S, Watanabe Y, Hashimoto Y, et al. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. Mol Cancer Ther. 2009;8:980\u20137.","journal-title":"Mol Cancer Ther"},{"key":"413_CR21","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1038\/onc.2010.295","volume":"29","author":"H Yamaguchi","year":"2010","unstructured":"Yamaguchi H, Chen CT, Chou CK, Pal A, Bornmann W, Hortobagyi GN, et al. Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation. Oncogene. 2010;29:5619\u201329.","journal-title":"Oncogene"},{"key":"413_CR22","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1158\/1078-0432.CCR-04-0644","volume":"10","author":"SM Frisch","year":"2004","unstructured":"Frisch SM. E1A as a tumor suppressor gene: commentary re S. Madhusudan et al. A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2\/neu oncogene. Clin Cancer Res. 2004;10:2905\u20137.","journal-title":"Clin Cancer Res"},{"key":"413_CR23","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1158\/1535-7163.MCT-10-0693","volume":"10","author":"L Garcia-Rodriguez","year":"2011","unstructured":"Garcia-Rodriguez L, Perez-Torras S, Carrio M, Cascante A, Garcia-Ribas I, Mazo A, et al. Connexin-26 is a key factor mediating gemcitabine bystander effect. Mol Cancer Ther. 2011;10:505\u201317.","journal-title":"Mol Cancer Ther"},{"key":"413_CR24","first-page":"847","volume":"63","author":"A Hemminki","year":"2003","unstructured":"Hemminki A, Kanerva A, Liu B, Wang M, Alvarez RD, Siegal GP, et al. Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res. 2003;63:847\u201353.","journal-title":"Cancer Res"},{"key":"413_CR25","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.V86.2.624.bloodjournal862624","volume":"86","author":"E Soravia","year":"1995","unstructured":"Soravia E, Grebe A, De Luca P, Helin K, Suh TT, Degen JL, et al. A conserved TATA-less proximal promoter drives basal transcription from the urokinase-type plasminogen activator receptor gene. Blood. 1995;86:624\u201335.","journal-title":"Blood"},{"key":"413_CR26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","volume":"741C","author":"CL de Sousa","year":"2014","unstructured":"de Sousa CL, Monteiro G. Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014;741C:8\u201316.","journal-title":"Eur J Pharmacol"},{"key":"413_CR27","first-page":"6229","volume":"63","author":"WP Lee","year":"2003","unstructured":"Lee WP, Tai DI, Tsai SL, Yeh CT, Chao Y, Lee SD, et al. Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine. Cancer Res. 2003;63:6229\u201336.","journal-title":"Cancer Res"},{"issue":"7","key":"413_CR28","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1158\/1078-0432.CCR-14-2316","volume":"21","author":"HL Weber","year":"2015","unstructured":"Weber HL, Gidekel M, Werbajh S, Salvatierra E, Rotondaro C, Sganga L, et al. A novel CDC25B promoter based oncolytic adenovirus inhibited growth of orthotopic human pancreatic tumors in different preclinical models. Clin Cancer Res. 2015;21(7):1665\u201374.","journal-title":"Clin Cancer Res"},{"key":"413_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.canlet.2011.11.004","volume":"317","author":"A Jose","year":"2012","unstructured":"Jose A, Sobrevals L, Ivorra A, Fillat C. Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models. Cancer Lett. 2012;317:16\u201323.","journal-title":"Cancer Lett"},{"key":"413_CR30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.18632\/oncotarget.795","volume":"4","author":"A Jose","year":"2013","unstructured":"Jose A, Sobrevals L, Miguel Camacho-Sanchez J, Huch M, Andreu N, Ayuso E, et al. Intraductal delivery of adenoviruses targets pancreatic tumors in transgenic Ela-myc mice and orthotopic xenografts. Oncotarget. 2013;4:94\u2013105.","journal-title":"Oncotarget"},{"key":"413_CR31","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ccr.2010.08.006","volume":"18","author":"L Espinosa","year":"2010","unstructured":"Espinosa L, Cathelin S, D\u2019Altri T, Trimarchi T, Statnikov A, Guiu J, et al. The Notch\/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell. 2010;18:268\u201381.","journal-title":"Cancer Cell"},{"key":"413_CR32","first-page":"1175","volume":"2010","author":"D Abate-Daga","year":"1803","unstructured":"Abate-Daga D, Garcia-Rodriguez L, Sumoy L, Fillat C. Cell cycle control pathways act as conditioning factors for TK\/GCV sensitivity in pancreatic cancer cells. Biochim Biophys Acta. 1803;2010:1175\u201385.","journal-title":"Biochim Biophys Acta"},{"key":"413_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27\u201355.","journal-title":"Adv Enzyme Regul"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-015-0413-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12943-015-0413-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-015-0413-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-015-0413-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T18:22:14Z","timestamp":1630606934000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-015-0413-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,31]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["413"],"URL":"https:\/\/doi.org\/10.1186\/s12943-015-0413-2","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,31]]},"assertion":[{"value":"4 February 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"146"}}